IMCR News & Events

Immunocore announced that Kimmtrak five-year overall survival, OS, was presented in an oral session at the American Association for Cancer Research, AACR, 2026 meeting. This is the longest, prospective Phase 3 randomized trial in patients with unresectable or metastatic uveal melanoma - a disease with a very poor prognosis and a historical survival rate of less than 5% at 5 years. Kimmtrak doubled the likelihood of being alive at five years, with an OS for Kimmtrak of 16% versus 8% in the control arm. These results also represent the longest follow-up reported for any T cell engager in a solid tumor.

Reports Q4 revenue $104.5M, consensus $107.77M. "With $400 million in KIMMTRAK sales and a diverse clinical portfolio, Immunocore had a productive year of growth and progress in 2025," said Bahija Jallal, CEO of Immunocore. "Our priority for 2026 is the clear execution of our clinical trials, particularly as we anticipate key data in oncology and begin our first trial in autoimmune disease. We remain focused on the long-term goal of developing medicines that can significantly improve patient lives."